OncoTricks

Oropharynx staging, KEYNOTE-689 and transfusion in pregnancy, Oct 26, 2026

Oropharynx: T3 or T4?

A man in his fifties has a p16-positive squamous cell carcinoma of the base of tongue. He needed a tracheostomy before any treatment, and there are nodes on both sides of the neck. The outside note says T3N2. Is it T3 or T4, and why does it matter?

If you remember one thingIn p16-positive oropharynx, T4 means a named neighbor is invaded. Size alone never makes T4, and neither does a tracheostomy.

Concepts first

HPV: human papillomavirus. p16: a protein the virus switches on, read on the biopsy by immunohistochemistry. ENE: extranodal extension, cancer breaking out through the lymph node capsule. AJCC: the American staging rules. Since Jan 1, 2026, p16-positive oropharynx uses AJCC Version 9; p16-negative still uses AJCC 8; trials such as KEYNOTE-689 enrolled by AJCC 8.

ONE THROAT, TWO DISEASESDriven by HPV: p16-positivemostly tonsil and base of tongue3-year survival, cisplatin-radiation, by HPV ISH:82%own staging: AJCC Version 9(2026); ENE raises N one stepDriven by tobacco: p16-negativeany oropharyngeal subsite3-year survival, cisplatin-radiation, by HPV ISH:57%head and neck system, AJCC 8;ENE upstages NStage III to IV, HPV by in situ hybridization (Ang 2010).

p16 stands in for HPV; it is not HPV.p16-positive means nuclear and cytoplasmic staining, moderate to strong, in at least 70% of tumor cells (College of American Pathologists, 2025). About 1 in 10 p16-positive tumors is HPV-negative (10.9% overall; about 3 in 10 at subsites other than the tonsil and tongue base). Version 9 calls p16-positive tumors HPV-independent, and stages them as p16-negative, when an HPV-specific test disagrees, or when p16 comes with a caveat: a subsite outside the tonsil and tongue base, a neck node with unknown primary, unusual morphology, or a population where HPV causes few of these cancers.

The numbers behind it
ALIVE AT 5 YEARS, CURATIVE INTENT (MEHANNA 2023)p16-positive, HPV-positive81%p16-positive, HPV-negative55%p16-negative, HPV-negative40%

T: size first, then neighbors

T, p16-POSITIVE (SAME IN AJCC 8 AND VERSION 9)T12 cm or lessT2more than 2 cm, up to 4 cmT3more than 4 cm, or onto thelingual epiglottis surfaceT4invades a neighbor:LarynxExtrinsic tongue muscleMedial pterygoidHard palateMandible, or beyondLet EveryMedical HeroMove
1

Lingual epiglottis is T3

Mucosal spread from the base of tongue or vallecula onto the lingual surface of the epiglottis is not invasion of the larynx. Version 9 also moved the lingual surface of the epiglottis into the oropharynx chapter (still T3 when the tumor spreads onto it) and the adenoid and tubal tonsils into nasopharynx.

2

A tracheostomy is not a T criterion

Read the operative note: what blocked the airway?

3

p16-positive has one T4

No T4a or T4b: everything p16-negative calls T4b is plain T4 here. Version 9 calls T4 on extrinsic tongue muscle alone only with unequivocal imaging backed by clinical signs such as tongue tethering, fixation or deviation (Rai 2026). p16-negative keeps T4b: Lazy People Never Skip Coffee (lateral pterygoid, pterygoid plates, lateral nasopharynx, skull base, carotid encased).

4

T0 in the oropharynx

Only the HPV-associated chapter uses it: a neck node confirmed HPV-associated (p16 plus an HPV-specific test), with no primary found. A node not confirmed as HPV-associated and EBV-negative (EBV: Epstein-Barr virus) goes to the unknown-primary chapter; an EBV-positive node is staged as nasopharynx.

Key colors: orange, a trap; blue, a rule; grey, background.

N: three different rulers

p16-positive, clinicalexam and imaging, Version 9N1same side only, all6 cm or less, no ENEN2opposite or both,6 cm or less; orsame side with ENEN3over 6 cm; oropposite or bothwith ENEENE climbs one step
p16-positive, pathologicalafter neck dissection, Version 9pN1a: 1 nodeb: 2 to 4 nodes(no ENE)pN21 to 4 with ENE,or 5 or more withoutpN35 or morewith ENEcount, then ENE climbs
p16-negative, clinicaltobacco-driven, AJCC 8N1one, same side, 3 cmor less, no ENEN2a: one, over 3 to 6 cmb: several, same sidec: opposite or bothN3a: over 6 cm, no ENEb: overt ENE on examovert ENE on exam: N3b

pN0 needs at least 6 nodes examined; with fewer, use clinical N0.

Version 9 adds ENE to p16-positive N for the first time.AJCC 8 left it out: in ICON-S, the international collaboration that built that system (1907 HPV-positive patients, staged with the old 7th edition N, which had no ENE), survival was similar for the old N0, N1 to N2a and N2b, and the model grouped same-side nodes as N1, opposite or both sides (old N2c) as N2, and over 6 cm as N3 (O'Sullivan 2016). The node count after surgery came from 704 surgical patients (Haughey 2016). Version 9 now adds one N step for unequivocal ENE on exam or imaging, or proven on pathology (Rai 2026). In one Chinese single-center cohort of 191 patients treated with radiation, this moved 23% of N1 to N2 and 42% of N2 to N3 (Lv 2026).

Stage groups

Clinical, before treatmentN0N1N2N3T0n/aIIIIIIT1IIIIIIIT2IIIIIIIT3IIIIIIIIIT4IIIIIIIIIIIIAssign N after the ENE step.M1 is stage IV in every table.
Pathological, after surgerypN0pN1pN2pN3T0n/aIIIIIT1 to T2IIIIIIT3IIIIIIIIIT4IIIIIIIIIIIINew in Version 9: any T4 isstage III; T3 pN2 is stage II.

For contrast, p16-negative (AJCC 8): I = T1N0 · II = T2N0 · III = T3N0, or T1 to T3 with N1 · IVA = T4a, or N2 · IVB = T4b, or N3 · IVC = M1.The same T2 tumor with two same-side nodes and no ENE is stage I if p16-positive and stage IVA if p16-negative.

Back to the base of tongue

1. Does endoscopy or imaging show invasion of the larynx, an extrinsic tongue muscle, the medial pterygoid, the hard palate or the mandible, or anything beyond them (lateral pterygoid, pterygoid plates, nasopharynx, skull base, carotid encasement)?
yes
T4: clinical stage III, whatever the NExtrinsic tongue muscles: genioglossus, hyoglossus, styloglossus, palatoglossus. Ask the radiologist to name the structure.
no
2. Larger than 4 cm, or spread onto the lingual surface of the epiglottis?
yes
T3Mucosal spread onto the lingual epiglottis is T3 by definition, not laryngeal invasion.
no
T1 or T2, by size (2 cm, 4 cm)

Why was the airway secured?A bulky tongue base can obstruct at T3. It becomes T4 only when endoscopy or imaging shows a named neighbor invaded (in an airway story, usually the larynx); the tracheostomy itself is not staged.

Our patient, worked through.Say endoscopy shows a bulky tongue base filling the airway with the larynx free, and MRI shows no muscle invasion: T3. Nodes on both sides, no ENE: N2. Clinical stage II, and the outside note was right. If imaging shows unequivocal ENE, Version 9 makes it N3: stage III whatever the T. If MRI shows genioglossus invasion: T4, stage III. KEYNOTE-689 eligibility is still judged by AJCC 8 (next tab).

Try it: stage and trial check

Decide the stage in your head first, then set the boxes and check.

p16-positive with a caveat (subsite outside tonsil and tongue base, unknown primary, unusual morphology, HPV test negative) is HPV-independent: choose p16-negative.

Clinical stage, oropharynx only: p16-positive by AJCC Version 9, p16-negative by AJCC 8. The trial line uses KEYNOTE-689 entry rules, which were written in AJCC 8; performance status and the exclusions on the next tab still apply.

Memory hooks

Check yourself

Question 1p16-positive base of tongue, 3.5 cm, tracheostomy for stridor. MRI: tumor invades the genioglossus; larynx free. One 2 cm same-side node, no ENE. Stage?

T4 (extrinsic tongue muscle) N1, clinical stage III. The genioglossus made it T4, not the tracheostomy. If you said T2 by size, you forgot to check the neighbors first.

Question 2p16-positive tonsil cancer, 3.5 cm, two nodes on the same side (3 and 5 cm), no ENE on exam or imaging. Stage?

T2 N1, clinical stage I. With unequivocal ENE on imaging, Version 9 makes it N2, stage II. If p16-negative, the same tumor is T2 N2b, stage IVA.

Question 3The Question 2 patient has surgery: 6 positive nodes, no ENE on pathology. Pathological stage?

pT2 pN2, pathological stage II. After surgery, size and side stop counting: more than 4 nodes is pN2, and with ENE it would be pN3, still stage II with pT2. If you said pN1 because the nodes are small, that is the trap.

Question 4p16-positive base of tongue, 3 cm, mucosal spread onto the lingual epiglottis, one 2 cm node on the opposite side, no ENE. Stage?

T3 (lingual epiglottis) N2 (opposite side), clinical stage II. Not T4: the larynx was not invaded.

Question 5A p16-positive neck node, and no primary found after panendoscopy. How is it staged?

Version 9 treats p16 alone in an unknown primary as a caveat: confirm with an HPV-specific test. If HPV-associated, it is oropharynx T0; one same-side node of 6 cm or less without ENE is T0 N1, stage I. If not confirmed, it goes to the unknown-primary chapter.

Question 6The tumor is p16-positive but HPV in situ hybridization is negative. Does it matter?

Yes. Version 9 calls it HPV-independent and stages it with the p16-negative system. Prognosis sits in between: 55% alive at 5 years versus 81% when both are positive (Mehanna 2023). Do not use p16 alone to choose a de-escalation trial or a lighter plan.

Sources

Retrieved from PubMed and the American College of Surgeons, read on Oct 26, 2026.

  1. American College of Surgeons. AJCC Version 9 protocols for HPV-associated oropharynx and salivary glands, effective January 1, 2026; expert-panel summary of the N and stage group changes. facs.org
  2. Rai P, Holtzman AL, Bhatt AA. HPV-associated oropharyngeal squamous cell carcinoma: an imaging framework for AJCC Version 9 TNM staging. Radiol Imaging Cancer 2026. doi:10.1148/rycan.260013
  3. Lv W, et al. Validation of the 9th edition cTNM classification for HPV-positive oropharyngeal carcinoma. Clin Transl Radiat Oncol 2026. doi:10.1016/j.ctro.2026.101181
  4. Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and neck cancers, major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017. doi:10.3322/caac.21389
  5. O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S). Lancet Oncol 2016. doi:10.1016/S1470-2045(15)00560-4
  6. Haughey BH, Sinha P, Kallogjeri D, et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol 2016. doi:10.1016/j.oraloncology.2016.09.004
  7. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010. doi:10.1056/NEJMoa0912217
  8. Mehanna H, Taberna M, von Buchwald C, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC). Lancet Oncol 2023. doi:10.1016/S1470-2045(23)00013-X
  9. Lewis JS Jr, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline update. College of American Pathologists. Arch Pathol Lab Med 2025. doi:10.5858/arpa.2024-0388-CP